TEMENOS
Banco de la Nación del Perú went live with Temenos (SIX: TEMN), the banking software company. In the first phase of the implementation, Temenos Banking Cloud supported the opening of two million new digital accounts called Cuentas DNI. With Temenos’ scalable open platform the bank plans to expand to 24 million accounts.
These accounts were created with the identification number (DNI) of each citizen, as part of the Yanapay Individual Economic Support program to provide government relief funds in response to the COVID-19 pandemic. Every Peruvian citizen, age 18 and older, with a DNI is automatically allocated a Cuentas DNI, fostering financial inclusion. Of the two million people who received a Cuentas DNI, more than 1.8 million previously did not have a bank account.
Banco de la Nación del Perú has approximately 570 branches, 60% of which are located in remote areas of the country. One of the bank’s key objectives is to promote financial inclusion through sustainable and modern business practices. Only 52% of adults in Peru have a bank account, according to data from the National Household Survey (ENAHO) and collected by the SBS. In response to the pandemic, the Peruvian government has launched special programs to distribute funds to the most vulnerable populations, using Cuentas DNI, which has facilitated the payment of one of these bonds to millions of unbanked Peruvians.
With the Temenos open platform for composable banking, Banco de la Nación del Perú will be able to scale massively, launch new products quickly and modernize other lines of business. The operational cost efficiencies will enable Banco de la Nación to offer its customers better benefits such as lower fees.
Liliana Casafranca, account leader from Cuentas DNI at Banco de la Nación del Perú, commented, "This is the beginning of Banco de la Nación’s modernization towards digital banking that will allow us to create more than 24 million accounts, and deliver financial inclusion to Peruvians. The challenge is to quickly develop enhancements that will encourage citizens to make greater use of their cellphones to carry out secure financial transactions, through Cuentas DNI. Our aim is to develop the right partnerships to make our services more accessible to clients. Banco de la Nación's vision is for the Cuentas DNI to become the gateway to more sophisticated services to Peruvians."
Enrique Ramos O’Reilly, managing director in Latin America and the Caribbean, Temenos, "We are proud to partner with Banco de la Nación del Perú. This is just the beginning of what we will create together. Temenos open platform will enable Banco de la Nación to scale massively and handle millions of accounts in order to provide financial services for those currently operating outside the financial system. We look forward to supporting Banco de la Nación del Perú in its digital transformation to provide outstanding banking services and promote financial inclusion to the people of Peru."
– Ends –
About Temenos
Temenos AG (SIX: TEMN) is the world’s leader in banking software. Over 3,000 banks across the globe, including 41 of the top 50 banks, rely on Temenos to process both the daily transactions and client interactions of more than 1.2 billion banking customers. Temenos offers cloud-native, cloud-agnostic and AI-driven front office, core banking, payments and fund administration software enabling banks to deliver frictionless, omnichannel customer experiences and gain operational excellence.
Temenos software is proven to enable its top-performing clients to achieve cost-income ratios of 26.8%, half the industry average, and returns on equity of 29%, three times the industry average. These clients also invest 51% of their IT budget on growth and innovation versus maintenance, which is double the industry average, proving the banks’ IT investment is adding tangible value to their business.
For more information, please visit www.temenos.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220317005454/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vertex Announces Progress in Povetacicept Development Program and Presentation of New Data at American Society of Nephrology Kidney Week17.10.2025 15:04:00 CEST | Press release
- Food and Drug Administration grants rolling review of Biologics License Application for povetacicept in IgA nephropathy; Vertex to submit first module before end of year - - Second pivotal development program of povetacicept underway with Phase 2b/3 trial initiation in primary membranous nephropathy - - Updated data from RUBY-3 trial of povetacicept accepted for late breaking oral presentation; inaxaplin study design and APOL1-mediated kidney disease related data accepted for poster presentation - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced several important updates across its development program for povetacicept (pove), an investigational recombinant fusion protein therapeutic and dual antagonist of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines. Pove has demonstrated best-in-class potential in IgA nephropathy (IgAN) and primary membranous nephropathy (pMN) and has pipeline-in-a-product potential across a range of B c
Qualcomm Announces Quarterly Cash Dividend17.10.2025 15:00:00 CEST | Press release
Qualcomm Incorporated (NASDAQ: QCOM) today announced a quarterly cash dividend of $0.89 per common share, payable on December 18, 2025, to stockholders of record at the close of business on December 4, 2025. About Qualcomm Qualcomm relentlessly innovates to deliver intelligent computing everywhere, helping the world tackle some of its most important challenges. Building on our 40 years of technology leadership in creating era-defining breakthroughs, we deliver a broad portfolio of solutions built with our leading-edge AI, high-performance, low-power computing, and unrivaled connectivity. Our Snapdragon® platforms power extraordinary consumer experiences, and our Qualcomm Dragonwing™ products empower businesses and industries to scale to new heights. Together with our ecosystem partners, we enable next-generation digital transformation to enrich lives, improve businesses, and advance societies. At Qualcomm, we are engineering human progress. Qualcomm Incorporated includes our licensing
Illumynt Reports Q3 2025 Business Update17.10.2025 14:39:00 CEST | Press release
Q3 2025 was a busy quarter once again for us here at illumynt. In addition to naming a new CEO, we executed on a number of initiatives that are propelling our organization forward. Revenue for the quarter exceeded $30 million- keeping us on track for our 2025 plan. More importantly we executed three different large-scale data center decommission projects with almost no material ending up as scrap. All of the AI-focused enterprise equipment and components recovered from the decommissions were resold at top market value. We head into Q4 with high expectations and our eyes wide open. We’re celebrating the 20-year anniversary of our facility in Hong Kong and looking to add another location in the region to help us process inbound AI data center equipment. Stay tuned for updates. There will be more on the way. View source version on businesswire.com: https://www.businesswire.com/news/home/20251017446548/en/
Avanzanite Bioscience’s Partner Agios Announces Positive CHMP Opinion for PYRUKYND® (mitapivat) for Adults with Thalassemia17.10.2025 14:15:00 CEST | Press release
Avanzanite entered an exclusive partnership with Agios in June 2025 to manage PYRUKYND commercialization across Europe European Commission will now review the CHMP’s opinion, with the final decision expected by early 2026 PYRUKYND is currently approved in Europe for adults with PK deficiency; thalassemia would represent its second indication, pending European Commission approval Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion for the new indication for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for t
Kinaxis Accelerates Agentic Era for Supply Chain Orchestration with the Launch of Maestro Agents17.10.2025 13:00:00 CEST | Press release
AI agents that plan with you, not just for you, empower the customer journey to a next generation of the adaptive supply chain Kinaxis® Inc. (TSX: KXS), a global leader in supply chain orchestration, today announced Maestro Agents, marking the next milestone in AI-enabled decision intelligence for supply chains. Now available to Kinaxis customers and embedded natively in Kinaxis Maestro®, these AI-powered context aware digital co-workers help planners move faster from issue to action, turning disruption into opportunity, and strengthening the resilience of the supply chains that power the global economy. “Kinaxis agents are already helping our planning team collaborate more effectively with customers and contract manufacturers,” said John Finnigan, Senior Director, Advanced Planning at Jabil. “With human-in-the-loop safeguards, we’re reaching decisions faster today and see strong potential to build a more resilient and networked supply chain.” Maestro Agents advance the customer journe
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom